BioSpace News Archive

Daré Bioscience, Inc. today announced that Climacteric , the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical trial of DARE-HRT1.

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, announced the appointment of Cynthia M. Patton as General Counsel and Secretary, effective today.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that resmetirom has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with NASH with liver fibrosis.

Matinas BioPharma announces that Marisa H. Miceli, MD, Professor of Medicine, at the University of Michigan and her team delivered an oral presentation earlier at the 33rd ECCMID in Copenhagen discussing MAT2203’s clinical impact in treating a compassionate use patient suffering from Rhodotorula mucilaginosa, a rare and opportunistic invasive fungal infection.

OptiNose, Inc. announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

ProSomnus, Inc. today announced the publication of four abstracts in the Journal of Dental Sleep Medicine.

Sotera Health Company announced its plans to release its financial results for the first-quarter ended March 31, 2023 before the market opens on Wednesday, May 3, 2023.

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia.

Antibe Therapeutics Inc. today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023.